Dublin, Nov. 18, 2021 (GLOBE NEWSWIRE) -- The "Metabolomics: Technologies and Global Markets 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global metabolomics market should reach $22.7 billion by 2026 from $12.7 billion in 2021 at a compound annual growth rate (CAGR) of 12.3% for the forecast period of 2021 to 2026.
The separation techniques segment of the global metabolomics market is expected to grow from $5.1 billion in 2021 to $8.7 billion in 2026 at a CAGR of 11.3% for the forecast period of 2021 to 2026.
The detection techniques segment of the global metabolomics market is expected to grow from $4.0 billion in 2021 to $7.1 billion in 2026 at a CAGR of 12.4% for the forecast period of 2021 to 2026.
This report examines the current and forecasted market potential for metabolomics. It offers a detailed analysis of the market background, technological advancement, competitive environment, drivers and restraints, and market growth trends. This report includes market projections through 2026, detailing the market share for metabolomics based on product, indication and application type.
Metabolomics studies focus on metabolite perturbations induced by infection and diseases. As direct signatures of disease onset and infection, metabolites can help researchers quickly determine pathogenesis, potential therapeutic targets, and cell or tissue damage.
They can also be used as biomarkers to monitor disease progression. At present, metabolomics, including amino acid metabolism, glucose metabolism, lipid metabolism, purine and pyrimidine metabolism, and so on, have been widely applied in the COVID-19 pandemic.
A shortage of qualified technicians, the high cost of instruments and tools, and the complexity affiliated with metabolomic data examination and processing pose threats to market growth.
Due to the increasing need for accurate diagnosis of diseases, rising demand for personalized medicine, increasing pharmaceutical and biotech research and development, and the availability of government and private funding, metabolomics is carving a greater presence in medicine and healthcare.
Since it is non-invasive in nature and closely linked to the phenotype, metabolomics is an ideal tool for use in agricultural industries, pharmaceuticals and preventive healthcare. A rise in the number of clinical trials, awareness about nutritional products, toxicological testing data, and rapid growth of metabolomics data analysis software and solutions are expected to propel the growth of this market.
High growth in this segment is mainly attributed to the increasing usage of different bioinformatics platforms in several metabolomic applications such as drug discovery and development and the benefit of smooth technological workflow with the reliable, precise and transparent data processing benefits gained from it.
In addition, the easy availability of technologically advanced products and significant investments in metabolomic-based research in personalized medicine, drug discovery studies and cancer therapeutics will also drive the North American market during the forecast period. Asia-Pacific's high growth rate is attributed to the high prevalence of cancer, unmet healthcare needs, high investments in metabolomics-based research, and growing R&D funding for cancer drug discovery and personalized medicine opportunities.
The Report Includes
Analyses of global market trends, with data from 2019 to 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Assessment of the key marketed products and recent product launches, the regulatory landscape across different demographics covering North America, Europe, Asia-Pacific, Latin America and the Middle East
Coverage of history and pathways of metabolomics, information on metabolomes and their sources like large bowel microflora, urine metabolome, food metabolome and comparison between lipidomes and lipidomics
Highlights of the market potential for metabolomics market by product, indication, application, and region; assessment of investment in metabolomics research and spending in pharmaceutical and biotech R&D
Information on targeted and untargeted approaches for metabolomic technology and complexity associated with data examination and processing
Identification of leading biotechnology companies poised to introduce products during the forecast period, and their impact on the face of the competitive environment
Detailed profiles of the leading companies in the metabolomics market, including Agilent Technologies, Bio-Rad, Danaher Corp., Merck KGaA, Promega Corp. and Thermo Fisher Scientific
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Overview of Metabolomics
Large Bowel Microflora
Lipidomes and Lipidomics
Metabolomic Process Steps
Separation and Detection
Targeted and Untargeted Approaches
Chapter 4 Metabolomics: Pipeline Analysis
Chapter 5 Metabolomics: Market Dynamics
Metabolomics Market Drivers
Increasing Investment in Metabolomic Research
Increase in Demand for Personalized Medicine
Increasing Pharmaceutical and Biotech R&D Spending
Increasing Use of Metabolomics in Toxicology Testing
Complexity Associated with Data Examination and Processing
High Cost of Tools and Instruments
Dearth of Skilled Researchers
Chapter 6 Impact of COVID-19 Pandemic
Impact of COVID-19 on Metabolomics
Chapter 7 Global Metabolomics Market Breakdown by Product
Bioinformatics and Systems Biology Tools
Chapter 8 Global Metabolomics Market Breakdown by Indication
Inborn Errors of Metabolism
Chapter 9 Global Metabolomics Market Breakdown by Application
Chapter 10 Global Metabolomics Market Breakdown by Region
Rest of Europe
Rest of Asia-Pacific
Middle East and Africa (MEA)
Chapter 11 Competitive Landscape
Global Company Share Analysis
Mergers and Acquisitions
Agreements, Collaborations, Product Launches, and Partnerships
Chapter 12 Company Profiles
Agilent Technologies Inc.
Biocrates Life Sciences Ag
Bio-Rad Laboratories Inc.
Drumetix Laboratories Llc
Gerstel Gmbh & Co. Kg
Human Metabolome Technologies America Inc.
Metabolomic Technologies Inc.
One Way Liver Genomics S.L.
Stemina Biomarker Discovery Inc.
Thermo Fisher Scientific Inc.
For more information about this report visit https://www.researchandmarkets.com/r/aj012z
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900